Asia Pacific Immunodiagnostics Market

The Asia Pacific immunodiagnostics market is expected to grow from US$ 2,409.90 million in 2023 to US$ 4,252.35 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2023 to 2030.

Technological Advancements in Immunodiagnostics Drive Asia Pacific Industrial Robotics Market

The current trend in immunodiagnostics is microfluidics and magnetic beads with potential commercialization. These sensitive, specific, and time-saving methodologies are essential in understanding and diagnosing health conditions, such as infectious diseases, metabolic disorders, and cardiac problems.

The increasing applications of immunodiagnostics solutions encouraged the development of targeted treatments and therapies for precision health. The prominent market players also promote assay technologies, microfluidics, and magnetic beads. For immunoassays, magnetic particles, such as Sera-Mag beads, offer a convenient alternative to plate-based ELISAs, as both rely on the same assay principle. Merck KGaA launched the Magna Chip Protein A magnetic beads. This recombinant Protein A is covalently bound to magnetic beads for chromatin immunoprecipitations (Chip assays), providing users with a faster, reproducible, and more efficient reagent for collecting immunocomplexes than agarose beads.

In microfluidics, some immunodiagnostics target single biomarkers. However, a recent trend shows the detection of multiple analytes according to the complexity and the need to make early reliable diagnoses.

In September 2023, Siemens Healthineers released its new CE-marked SARS-CoV-2/FluA/FluB/HRSV assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. The new FTD SARS-CoV-2/FluA/FluB/HRSV assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates clinically relevant viruses such as SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B.

Asia Pacific Immunodiagnostics Market Overview

According to Statista, a large chunk of the Chinese population was suffering from chronic diseases in 2020. Almost 80% of deaths among people aged 60 years in the country are caused due to chronic NCDs, of which the most severe are ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and Type II diabetes. According to China Blueprint, immunological diagnosis has exceeded biochemical diagnosis (accounting for 27%), and the in vitro diagnostics (IVD) market has gone mainstream in China. However, compared to developed countries, there is still room for alternative biochemical diagnosis to expand in China’s immunodiagnostics market, as the average ratio of biochemical to immunization diagnosis is about 1:2, according to statistical data from several agencies. As technological innovation advances with the growing need for high-end testing, diagnostics is expected to consolidate its mainstream status.

Furthermore, collaborations between organizations are increasing for developing and producing assays. For instance, in December 2023, Ortho Clinical Diagnostics Trading and Shanghai Medconn Biotechnology signed an agreement as part of a joint venture to develop and manufacture assays for the VITROS immunodiagnostics platform in China. The expertise of Ortho Clinical Diagnostics Trading in developing and designing in vitro diagnostics (IVD) technologies for POC settings, clinical labs, and transfusion medicine will propel the growth of the Asia Pacific immunodiagnostics market in the coming years.

Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Immunodiagnostics Strategic Insights

Strategic insights for the Asia Pacific Immunodiagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Immunodiagnostics Report Scope

Asia Pacific Immunodiagnostics Regional Insights

The geographic scope of the Asia Pacific Immunodiagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Immunodiagnostics Market Segmentation 

The Asia Pacific immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Asia Pacific immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered a largest share in the Asia Pacific immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Asia Pacific immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered a largest share in the Asia Pacific immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Asia Pacific immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered a largest share in the Asia Pacific immunodiagnostics market.

Based on country, the Asia Pacific immunodiagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China registered a largest share in the Asia Pacific immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific immunodiagnostics market.